GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Cabozantinib s-malate overview

Cabozantinib s-malate (XL184, BMS907351, Cometriq) is a s-malate salt form of cabozantinib. It is formulated as hard gelatin capsules for oral route of administration. Cometriq is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer.

Cabozantinib is under development for the treatment of pancreatic ductal adenocarcinoma, metastatic cervical cancer, metastatic castration-resistant prostate cancer (mCRPC), clear cell renal cell carcinoma, advanced or metastatic urothelial cancer, carcinoid tumor, gastroesophageal adenocarcinoma, metastatic melanoma, thyroid cancer, neuroendocrine gastroenteropancreatic tumors, hepatocellular carcinoma, pheochromocytoma, paraganglioma (glomus jugulare tumor), pancreatic neuroendocrine tumor, endometrial cancer, rhabdomyosarcoma, non-rhabdomyosarcoma, Wilms' tumor (nephroblastoma), Ewing sarcoma, osteosarcoma, soft tissue sarcoma, recurrent head and neck cancer squamous cell carcinoma, oral cavity cancer, laryngeal cancer, hypopharyngeal cancer,squamous cell carcinoma, metastatic colorectal cancer, colorectal cancer, gastric cancer, plexiform neurofibroma, penile cancer, adenocarcinoma of the gastroesophageal junction, advanced melanoma, non-small cell lung cancer, esophageal cancer, small cell lung cancer (SCLC), recurrent or progressive meningioma, papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC), adrenocortical carcinoma.

The drug candidate was also under development for the treatment of triple-negative breast cancer (TNBC), relapsed/refractory acute myeloid leukemia, anaplastic thyroid cancer, astrocytoma, glioblastoma multiforme, renal failure, Merkel cell carcinoma, metastatic renal cell carcinoma, urethral cancer, ureter cancer, peritoneal cancer, pancreatic tumor, metastatic adenocarcinoma of the pancreas, bladder cancer, metastatic uveal melanoma, epithelial ovarian cancer, fallopian tube cancer, hormone-receptor-positive breast cancer with bone metastases, relapsed/refractory multiple myeloma, papillary renal cell carcinoma and gastroesophageal (GE) junction carcinomas.

Ipsen overview

Ipsen is a global specialty biopharmaceutical company engaged in the manufacturing and distribution of drugs for the treatment of cancer, rare diseases, and neurological diseases, including specialty pharmaceutical products. The company develops and commercializes novel medicines for cancer, neuroscience and rare diseases and offers products to treat gastrointestinal disorders, and neurodegenerative pathologies. Ipsen sells its drugs through a network of distributors and directly to hospitals in a few countries. The company operates its research and development facilities in Paris-Saclay, France; Oxford, the UK; and Cambridge, the US. The company offers products in Europe, North America, and rest of the world. Ipsen is headquartered in Boulogne-Billancourt, France.

For a complete picture of Cabozantinib s-malate’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.